1. Bavetsias, V., Marriott, J. H., Melin, C., Kimbell, R., Boyle, F. T. & Jackman, A. L. (1997). Synthesis and antitumour activity of cyclopenta[g]quinazoline-based antifolates, a novel class of thymidylate synthase (TS) inhibitors. Br J Cancer 75(Suppl 1): 24
2. Boyd, M. R. (1989). Status of the NCI preclinical antitumor drug discovery screen: implications for selection of new agents for clinical trial. In Cancer: Principles and Practice of Oncology Updates, Vol. 3, De Vita VT, Hellman S and Rosenberg SA (eds), pp. 1–12. Lippincott: Philadelphia
3. Boyd, M. R., Paull, K. D. & Rubinstein, L. R. (1992). Data display and analysis strategies for the NCI disease-orientated in vitro antitumour drug screen. In Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, Valeriote FA, Corbett T and Baker L (eds), pp. 11–34. Kluwer Academic Publishers: Amsterdam
4. Calvert, A. H., Jones, T. R., Jackman, A. L., Brown, S. J. & Harrap, K. R. (1980). An approach to the design of antimetabolites active against cells resistant to conventional agents illustrated by quinazoline antifolates with N10-substitutions. In Advances in Tumor Prevention, Detection and Characterisation, Vol. 5, Davis W, Harrap KR and Stathopoulos G (eds), pp. 272–283. Excepta Medica: Amsterdam
5. Charcosset, J. Y. (1986). Effects of antineoplastic agents on the cell cycle progression. Biol Cell 58: 135–138.